News
Published over 4 years ago. See the latest and most current information on News.
Beximco Pharmaceuticals Ltd has announced that the company has now completed its acquisition of the majority stake in Sanofi Bangladesh, in line with the company’s strategy to expand core capabilities and product offerings.
Mr Nazmul Hassan MP, Beximco Pharma MD, commented: "The completion of this deal - the second acquisition in Beximco Pharma’s history - is a significant moment. We have a clear strategy to continue our diversification and expansion while strengthening our position as a market-leading pharma company in Bangladesh. The acquisition of a majority stake in Sanofi Bangladesh is precisely in line with this strategy, strengthening our position in key therapeutic areas to drive sustainable revenue and profit growth. We look forward to welcoming over 800 skilled and diligent Sanofi Bangladesh employees to our existing workforce. As an enlarged group, we are excited to continue our growth trajectory by delivering affordable treatments and breakthrough therapies in our growing domestic market."
More information online
ILM Guide 2026/27